{"name":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","slug":"nanjing-sanhome-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"SH3765 tablet","genericName":"SH3765 tablet","slug":"sh3765-tablet","indication":"Other","status":"phase_1"},{"name":"SH-1028 tablets","genericName":"SH-1028 tablets","slug":"sh-1028-tablets","indication":"Unknown","status":"phase_3"},{"name":"Placebo Gefitinib","genericName":"Placebo Gefitinib","slug":"placebo-gefitinib","indication":"Control arm in gefitinib clinical trials (Phase 3)","status":"phase_3"}]}],"pipeline":[{"name":"SH3765 tablet","genericName":"SH3765 tablet","slug":"sh3765-tablet","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SH-1028 tablets","genericName":"SH-1028 tablets","slug":"sh-1028-tablets","phase":"phase_3","mechanism":"SH-1028 tablets are a small molecule drug that targets the molecular target.","indications":["Unknown"],"catalyst":""},{"name":"Placebo Gefitinib","genericName":"Placebo Gefitinib","slug":"placebo-gefitinib","phase":"phase_3","mechanism":"This is a placebo control arm, not an active drug, and contains no therapeutic mechanism.","indications":["Control arm in gefitinib clinical trials (Phase 3)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNWi1jazNVV0tlVGZnOEhERnJNaVQ1UGpjbXAycHVoR091a3o3WmdoUkRPVElJWnZ2SVZBd3RXLTVCR2FDR1JjemRGb21zMVQtaXB3QXRhZkNzVmMzMDBCck9sUjhiOVQ3b0Zoc0x5ZXA3bkR0SWJzc1dteVdhRWlQSnFodVFsdlFBRFJYQ1VNNGJLeEsyZXVVSw?oc=5","date":"2026-04-08","type":"trial","source":"openPR.com","summary":"Hepatitis C Virus Infection Clinical Trial Pipeline Shows - openPR.com","headline":"Hepatitis C Virus Infection Clinical Trial Pipeline Shows","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxPcTVRbXZFOWZtUFRTMHpTV20wbVlUZHpQWEtCLTJBWk12R1lRbF9lelh3TlBsVWR6SzlhRGJxNXRNVHZjRGtpeFJiLXVzQU9raVpUcS13Yk4wNEkzVndOdjBpbnJuVUZDemRjQUtyWFd3eHUzMlhVMVhsWkRua0Z2aWZ6Zy01TkZ6aFY0cFZBT051UUgzaEFOZEhBWGtlS2JtcGhOTDFzdGRBeERZTkU4VXlrbGcyNTdkMFZIaU0xTHpSOUFPWW5NRWpRamJmWWRmUDVJbjU4LVdRZldJMlA3aEhTel9UTDVMdzlMY25MSm1aM0t6MldmSm9Td2dWaWRkbmZDdEpn?oc=5","date":"2024-07-15","type":"pipeline","source":"BioSpace","summary":"Hepatitis C Market Estimated to Reach USD 47.1 Billion by 2034, Impelled by Combination Therapy Involving Immune Modulator Drugs and Nucleoside Analogs - BioSpace","headline":"Hepatitis C Market Estimated to Reach USD 47.1 Billion by 2034, Impelled by Combination Therapy Involving Immune Modulat","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":1,"phase_3":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}